Innovative minds, transformative times

Amy Lo is Chairman of Global Wealth Management Asia, Co-Head of Wealth Management Asia Pacific, Head and Chief Executive of UBS Hong Kong, and a Managing Director at UBS. Amy has over 30 years of experience in the banking industry. Since joining UBS in 1995, she has held a number of senior management positions including Regional Head of Ultra High Net Worth and Global Family Office in Asia. Today, the ultra-high net worth business is the leading wealth manager for ultra-high net worth individuals in the region.

Actively involved in the development of the private banking industry in Hong Kong, Amy chairs the Executive Committee of the Hong Kong Private Wealth Management Association (PWMA), and is a Board Member of the Hong Kong Financial Services Development Council (FSDC). She is also a member of the Banking Industry Training Advisory Committee of the Hong Kong Education Bureau, a member of the Exchange Fund Advisory Committee Financial Infrastructure Sub-Committee of Hong Kong Monetary Authority, and an advisor of Our Hong Kong Foundation.

A passionate supporter of youth education and technological innovation in Greater China, Amy is a member of The Court and the MBA Advisory Board at The University of Hong Kong, and a member of the Advisory Committee of the Department of Social Work at The Chinese University of Hong Kong. She is also a Board Member of the UBS Optimus Foundation, the independent grant-making foundation that helps UBS clients improve the education and welfare of children globally.

In recognition of her contribution to the wealth management industry, Amy was named Private Banker of the Year in the Asian Private Banker Awards for Distinction 2020. She also received the Executive Award at the DHL/SCMP Business Awards 2018 for her efforts in building UBS as a corporate citizen in Hong Kong. She was also named by a top-tier Chinese media, China Business News, as one of the "Hong Kong Top 20 in the next 20 years" for her contribution to innovation developments in 2017.

Billy Boyle is an engineering graduate from the University of Cambridge. He is one of the original co-founders of Owlstone Inc, spun out of Cambridge in 2004 with the goal of developing the applications of field asymmetric ion mobility spectroscopy (FAIMS).

Billy started to focus on the medical applications of FAIMS technology after his wife, Kate, was diagnosed and later died of colon cancer as a result of a late diagnosis. He worked closely with clinical partners who integrated FAIMS technology across a broad spectrum of research studies.

Positive results helped to spin-out, and secure initial funding for, Owlstone Medical. With ongoing clinical and commercial success, Billy led this process and became the founding CEO upon the close of a $7M investment in March 2016. The mission of Owlstone Medical is to save 100,000 lives and $1.5B in healthcare costs.

Owlstone Medical has developed Breath Biopsy with the goal of creating non-invasive breath tests to support early detection and precision medicine of diseases including cancer, asthma, COPD and liver disease. Our Breath Biopsy Research Products and Services are available to academic, clinical and pharma research partners who want to develop breath based diagnostics for their own applications. We work with leading academic institutions and industry leaders such as Cleveland Clinic, Astra Zeneca, J&J and GSK with over 100 published papers and posters using Owlstone’s technology. As of 2023, the company has secured over $150M of investment.
Billy received The Royal Academy of Engineering Silver Medal and was a winner of the 2018 MacRobert Award; he was then made a Fellow of the Royal Academy of Engineering in 2020 and an MBE in 2021. He was elected an Industrial Fellow at Trinity Hall Cambridge and Entrepreneur in Residence (EIR) at King’s College Cambridge in 2022.

Billy sits on the CRUK Early Detection and Diagnosis Research Committee and was previously a judge for the Cancer Research UK (CRUK) Pioneer award and a trustee of the Linacre Institute. He likes to combine a love of running with raising money for charities such as CRUK.

Dr. Maikel Rheinstädter is the CEO and co-founder of Synth-Med Biotechnology Inc. Maikel is a native of Germany and received his Ph.D. in physics from Saarland University.

He then held positions at the Research Centre Jülich, Germany, the Institut Laue-Langevin in Grenoble, France, and the University of Göttingen, Germany, before moving to the University of Missouri-Columbia, USA, as a professor. He currently holds the position of full professor of biophysics at McMaster University in Canada. In 2020, he co-founded Synth-Med Biotechnology Inc. as a spin-off of his research, aimed at developing smart, red blood cell-based drugs. He currently serves as the CEO of Synth-Med.

Dr. Mario Michan, CEO & Founder of Daphne Technology, is a visionary leader committed to using technology to address environmental challenges.

He combines his maritime industry background and scientific/engineering expertise to create innovative solutions for reducing industrial greenhouse gas emissions. Before founding Daphne Technology, Mario was a Research Scientist at The Swiss Federal Institute of Technology in Lausanne and previously served as an officer in the Colombian Navy and worked as a merchant ship deck and engineer officer. Mario holds a PhD in Physics from The University of British Columbia, a Post-graduate Diploma in Entrepreneurship from Cambridge Judge Business School, and an Executive MBA in Business Administration and Management from INSEAD, which has equipped him with the necessary skills and knowledge to lead Daphne Technology to success. His commitment to the environment and technology innovation drives Daphne Technology's mission to positively impact the world by reducing greenhouse Gas emissions.

Liran co-founded WEKA in 2013. Today, he guides the company’s long-term vision and strategy as its Chief Executive Officer. He previously served as WEKA’s Chief Technology Officer.

Before establishing WEKA, Liran co-founded and led research and development at social startup Fusic, where he was responsible for the engineering, design, and development of its rich social media application portfolio. Prior to Fusic, Liran was the principal software architect and a founding member of the technical team at XIV Storage Systems before its acquisition by IBM in 2007; he then managed XIV’s hardware and platform teams at IBM for several years.

Before joining XIV, Liran served as a Software Engineer with the rank of Captain in the Israeli Defense Forces for five years. He earned a Bachelor of Science degree in Mathematics and Computer Science from Tel Aviv University.

Patrick Zhang joined Horizons Ventures in 2016 and leads and manages biotechnology and healthcare-related investments. He is trained as a chemical engineer and has worked in various industries, including energy, financial institutions, and investment management. Prior to joining Horizons, Patrick work at Morgan Stanley,where he provided financial advisory services for capital raising and cross-border M&A to his clients. He earned his Bachelor’s degree in Chemical Engineering from UCLA and an MBA from Columbia Business School.

Michael J. Biercuk is the CEO and Founder of Q-CTRL and a Professor of Quantum Physics and Quantum Technology at the University of Sydney where he also serves as Chief Investigator in the ARC Centre of Excellence for Engineered Quantum Systems.

Through these roles he has become a globally recognized pioneer in the discipline of quantum control engineering, seeking to make quantum systems perform useful work. Michael earned his undergraduate degree from the University of Pennsylvania, and his Masters and PhD from Harvard University. He held a research fellowship in the Ion Storage Group at NIST Boulder, and has served as a full-time technical consultant to DARPA, helping to steer government investments in quantum information and advanced computer architectures. Michael is a SXSW and TEDx speaking alumnus and has won multiple awards for research, innovation, and commercial technology development.